Physician profile
Thomas G Smith
NPI 1407864036
$3,127.61
in general payments reported to CMS, 2019-2025
10 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $180 · 2021: $200 · 2022: $872 · 2024: $293 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,320.42 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, General - Erectile Dysfunction, General - Male Sui |
| Innovation Technologies INC | $436.33 | 2024-2025 | Irrisept |
| Janssen Scientific Affairs, LLC | $136.08 | 2024 | |
| Stryker Corporation | $111.01 | 2021 | |
| Convatec INC. | $43.72 | 2019 | |
| Cook Medical LLC | $25.00 | 2025 | Litho 150 |
| Pfizer INC. | $22.16 | 2024 | |
| Mirum Pharmaceuticals, INC. | $21.05 | 2025 | Livmarli |
| Welch Allyn | $11.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.